NASDAQ : LXRX
Lexicon Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.48 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 658.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 640.74M |
| Enterprise Value | 509.37M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 444.96M |
| Shares Outstanding | 444.96M |
| Shares Change (YoY) | +7.98% |
| Shares Change (QoQ) | +9.35% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 34.54% |
| Float | 218.99M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.45 |
| Forward PS | 38.63 |
| PB Ratio | 3.67 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.37 |
| Quick Ratio | 13.07 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.50 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -40.21% |
| Return on Assets (ROA) | -14.32% |
| Return on Invested Capital (ROIC) | -16.04% |
| Return on Capital Employed (ROCE) | -23.16% |
| Weighted Average Cost of Capital (WACC) | 10.27% |
| Revenue Per Employee | $511,963 |
| Profits Per Employee | -$754,519 |
| Employee Count | 81 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 8.50 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +4.35% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 31.34 |
| Average Volume (20 Days) | 1,901,105 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 26.70M |
| Short Previous Month | 25.83M |
| Short % of Shares Out | 6.00% |
| Short % of Float | 12.19% |
| Short Ratio (days to cover) | 8.55 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 41.47M |
| Gross Profit | 35.67M |
| Operating Income | -54.50M |
| Pretax Income | -61.12M |
| Net Income | -61.12M |
| EBITDA | -54.02M |
| EBIT | -54.50M |
| Loss Per Share | -$0.16 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 190.61M |
| Total Debt | 59.24M |
| Net Cash | 131.37M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 174.53M |
| Book Value Per Share | 0.39 |
| Working Capital | 181.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -64.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 481,000 |
| Net Borrowing | -7.26M |
| Free Cash Flow | -64.99M |
| FCF Per Share | -$0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.02% |
| Operating Margin | -131.43% |
| Pretax Margin | -147.38% |
| Profit Margin | -147.38% |
| EBITDA Margin | -130.27% |
| EBIT Margin | -131.43% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.98% |
| Shareholder Yield | -7.98% |
| Earnings Yield | -11.02% |
| FCF Yield | -10.14% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.47 |
| Price Target Difference | 210.07% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 12.66% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.5 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |